These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 10195289

  • 1. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD.
    Agren L, Norin M, Lycke N, Löwenadler B.
    Protein Eng; 1999 Feb; 12(2):173-8. PubMed ID: 10195289
    [Abstract] [Full Text] [Related]

  • 2. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 3. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
    Agren L, Sverremark E, Ekman L, Schön K, Löwenadler B, Fernandez C, Lycke N.
    J Immunol; 2000 Jun 15; 164(12):6276-86. PubMed ID: 10843681
    [Abstract] [Full Text] [Related]

  • 4. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N.
    Curr Opin Mol Ther; 2001 Feb 15; 3(1):37-44. PubMed ID: 11249730
    [Abstract] [Full Text] [Related]

  • 5. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L, Löwenadler B, Lycke N.
    Immunol Cell Biol; 1998 Jun 15; 76(3):280-7. PubMed ID: 9682972
    [Abstract] [Full Text] [Related]

  • 6. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 7. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.
    J Immunol; 2010 Sep 01; 185(5):2935-41. PubMed ID: 20675596
    [Abstract] [Full Text] [Related]

  • 8. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
    Lycke N, Schön K.
    Vaccine; 2001 Mar 21; 19(17-19):2542-8. PubMed ID: 11257390
    [Abstract] [Full Text] [Related]

  • 9. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci; 2004 Dec 21; 1029():193-208. PubMed ID: 15681758
    [Abstract] [Full Text] [Related]

  • 10. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N.
    J Immunol; 2001 Sep 15; 167(6):3398-405. PubMed ID: 11544331
    [Abstract] [Full Text] [Related]

  • 11. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N.
    Cell Microbiol; 2004 Jan 15; 6(1):23-32. PubMed ID: 14678328
    [Abstract] [Full Text] [Related]

  • 12. The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability.
    Eriksson A, Lycke N.
    Vaccine; 2003 Dec 12; 22(2):185-93. PubMed ID: 14615145
    [Abstract] [Full Text] [Related]

  • 13. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
    Eriksson AM, Schön KM, Lycke NY.
    J Immunol; 2004 Sep 01; 173(5):3310-9. PubMed ID: 15322194
    [Abstract] [Full Text] [Related]

  • 14. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.
    Vaccine; 2006 Jan 30; 24(5):544-51. PubMed ID: 16169634
    [Abstract] [Full Text] [Related]

  • 15. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant.
    Mattsson J, Yrlid U, Stensson A, Schön K, Karlsson MC, Ravetch JV, Lycke NY.
    J Immunol; 2011 Oct 01; 187(7):3641-52. PubMed ID: 21880985
    [Abstract] [Full Text] [Related]

  • 16. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X, Su Q, Qiu F, Yi Y, Shen L, Jia Z, Liang P, Zou Y, Bi S.
    Vaccine; 2018 Jul 05; 36(29):4354-4361. PubMed ID: 29880240
    [Abstract] [Full Text] [Related]

  • 17. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb 05; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

  • 18. Identification of motifs in cholera toxin A1 polypeptide that are required for its interaction with human ADP-ribosylation factor 6 in a bacterial two-hybrid system.
    Jobling MG, Holmes RK.
    Proc Natl Acad Sci U S A; 2000 Dec 19; 97(26):14662-7. PubMed ID: 11106366
    [Abstract] [Full Text] [Related]

  • 19. A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.
    Bemark M, Bergqvist P, Stensson A, Holmberg A, Mattsson J, Lycke NY.
    J Immunol; 2011 Feb 01; 186(3):1399-410. PubMed ID: 21199899
    [Abstract] [Full Text] [Related]

  • 20. Contribution of subdomain structure to the thermal stability of the cholera toxin A1 subunit.
    Banerjee T, Pande A, Jobling MG, Taylor M, Massey S, Holmes RK, Tatulian SA, Teter K.
    Biochemistry; 2010 Oct 19; 49(41):8839-46. PubMed ID: 20839789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.